ZBH logo

Zimmer Biomet

ZBH · What the business does, what can go wrong, and how options sellers approach it

What it does

Zimmer Biomet is a medical device company focused on musculoskeletal health. It designs, makes and sells orthopedic products, most notably implants used to replace damaged joints such as knees and hips. It also sells products for sports medicine, trauma, extremities (shoulders, elbows, hands, feet and ankles), and related surgical tools and technologies.

Its customers are mainly hospitals and surgical centers, and surgeons strongly influence which products get used.

How it makes money

The company sells implants, instruments and surgical technology, including robotic and digital tools that support joint replacement procedures. Revenue is tied to procedure volume, so each surgery that uses its products generates sales.

Once a surgeon is trained on a system, switching can be disruptive. That can make relationships with surgeons and hospitals sticky over time.

Why investors own it

  • Exposure to aging populations, since joint replacement demand tends to rise as people live longer and stay active.
  • A scaled position in large joint replacement, a mature but essential part of healthcare.
  • Recurring demand for implants and related supplies, linked to elective but medically important procedures.
  • Potential for a steady cash-generating business, though that is never guaranteed.

What can go wrong

  • Procedure volumes can slow when hospitals face staffing shortages or when patients delay elective surgery.
  • Competition in orthopedics is intense, and losing surgeon loyalty or market position can hurt sales.
  • Pricing pressure from hospitals, group purchasing organizations and insurers can squeeze margins.
  • Product recalls, quality problems or litigation are an ongoing risk for implant makers.
  • Regulatory approvals and reimbursement changes can affect which products reach the market and how profitable they are.
  • Integrating past acquisitions and managing a complex manufacturing network can be difficult.

What to watch

  • Organic revenue growth, especially in knees and hips
  • Procedure volume trends
  • Adoption of its robotic and surgical technology platforms
  • Gross and operating margin trends
  • Free cash flow and debt levels
  • Regulatory actions, recalls or litigation updates
  • Reimbursement and hospital spending trends

Options income angle

Options on ZBH are generally available across multiple expirations, but liquidity is typically more modest than for mega-cap stocks. Spreads can be wider on strikes far from the current price, so check open interest and volume first.

Implied volatility tends to rise ahead of quarterly earnings and when investors react to procedure trends, guidance changes, competitor news or regulatory developments.

One caution: selling premium before earnings can be risky, because a single report or outlook change can move the stock sharply and quickly overwhelm the premium collected.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 20, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Zimmer Biomet's net sales rose 7.2 percent in 2025, helped by the Paragon 28 acquisition, but net earnings fell to $705.1 million from $903.8 million. Charges for product lines being discontinued, acquisition costs, interest on acquisition debt and U.S. tariffs cut into profit. Management expects slower sales growth in 2026 as it converts its U.S. sales force and carries $7,519.1 million of debt.

How the business did

  • Net sales were $8,231.5 million, up from $7,678.6 million. Paragon 28 added 2.5 percent to growth, and market growth, new products and weak 2024 sales (hurt by a software system rollout that disrupted order fulfillment) also helped.
  • Profit margins shrank. Operating profit was 13.3 percent of net sales versus 16.7 percent, and gross margin was 61.6 percent versus 63.8 percent. The filing cites inventory and instrument charges of approximately $170 million, tariffs and Paragon 28 inventory revalued upward at purchase.
  • S.E.T. (sports medicine, extremities, trauma and related products) grew 15.2 percent, with Paragon 28 contributing 10.5 percent. Knees and Hips each grew 4.7 percent. Biologics sales fell 14.2 percent.
  • Operating cash flow was $1,697.1 million versus $1,499.4 million. The company paid $1,393.2 million, net of cash acquired, for Paragon 28 and Monogram, repurchased $487.0 million of stock and declared $0.24 per share in quarterly dividends.

Risks specific to this company

  • Sales force overhaul: The company is converting large parts of its U.S. sales force from independent distributors to employees. It warns this could cause departures of key sellers to competitors, coverage gaps and lower sales, and expects uneven revenue in some emerging markets.
  • Debt: Outstanding debt was $7,519.1 million, of which $587.1 million is current debt maturing on December 13, 2026. Some debt carries floating interest rates tied to SOFR, so rate rises would raise borrowing costs.
  • Tax disputes: The IRS has proposed adjustments for years 2013 through 2015 and 2016 through 2019. The company disputes them, but says future payments may be significant. Litigation liabilities were estimated at $136.2 million.
  • Operations and supply: An Americas software transition disrupted order fulfillment in the second half of fiscal 2024. Some materials come from a single source or a limited number of sources, and one sterilization supplier went bankrupt in 2024.
  • International exposure: About 42 percent of 2025 net sales came from outside the U.S. The filing points to tariffs that raised the cost of goods sold, China's volume-based procurement (government-run bulk price negotiations) and currency swings, especially the Euro and Japanese Yen.
  • Goodwill: The company held $9.9 billion in goodwill and $4.7 billion of intangible assets. Weaker performance could force write-downs, though none were recorded in 2025 or 2024.

What management is watching

  • Management expects 2026 net sales growth of 2.5 percent to 4.5 percent, with go-to-market changes and price declines partly offsetting market growth and new products. Foreign currency is expected to add 0.5 percent.
  • Operating profit is expected to rise, helped by higher sales, restructuring savings and no repeat of the product-discontinuation charges. Inflation, U.S. sales channel investment, higher net interest expense and a higher effective tax rate may offset part of that.
  • The 2025 Restructuring Plan is expected to cost approximately $155 million in total by the end of 2027. It aims to cut gross annual pre-tax operating expenses by approximately $175 million by then.
  • Quarterly results may swing because of the timing of incentivized stocking orders and capital sales.
  • On February 9, 2026, the board authorized a new $1.5 billion share repurchase program and ended the earlier one, which had $770.2 million remaining. Contingent consideration (extra payments owed to sellers of acquired companies if targets are met) could range from $25 million to $795 million.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 4, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Net sales rose 3.1 percent in the quarter and 5.7 percent over nine months, helped by customers' "opportunistic end-of-quarter purchases" and new acquisitions. Quarterly net earnings fell to $191.6 million from $230.9 million, mainly because favorable acquisition-related accounting adjustments in the prior year did not recur. Knees sales declined while most other categories grew.

How the business did

  • Sales: Quarterly net sales were $2,062.9 million versus $2,001.4 million a year earlier. Nine-month net sales were $6,326.6 million versus $5,987.7 million. Growth came from the end-of-quarter purchases, the 2026 acquisitions, ROSA® Robot and bone cement sales, and new products. Selling prices had a negative effect of 0.7 percent.
  • Categories: Knees fell 3.1 percent to $767.5 million, which the filing attributes to a U.S. sales force transition, competition, and a distributor transition in China. Hips rose 6.0 percent, S.E.T. (sports medicine, extremities, foot and ankle, trauma and related lines) rose 6.8 percent, and Technology & Data, Bone Cement and Surgical rose 11.9 percent.
  • Profit: Operating profit was 14.9 percent of net sales versus 17.6 percent a year earlier. Selling, general and administrative expense rose to 41.4 percent of net sales from 40.5 percent, driven by incentive pay, litigation costs and sales force investment. Nine-month net earnings were $628.1 million versus $565.8 million, helped by a favorable adjustment of approximately $30 million for probable U.S. tariff refunds.
  • Cash and capital return: Nine-month operating cash flow was $1,367.2 million versus $1,179.7 million. The company repurchased $579.3 million of stock and has $924.7 million left under its buyback authorization. It declared a quarterly dividend of $0.24 per share.
  • Flagged item: One distributor customer made up approximately 12% of accounts receivable after a distributor change. It was given payment terms through October 2027, which raises credit risk until it pays in full.

What management is watching

  • Outlook: Management expects 2026 net sales growth of 4.4 percent to 4.9 percent and higher operating profit. It expects inflation, investment in the U.S. sales channel and higher net interest expense to offset part of the gains. The timing of incentivized stocking orders and capital sales could cause quarterly swings.
  • Cost programs: The 2025 Restructuring Plan is expected to cost approximately $170 million by the end of 2027, with approximately $146 million incurred so far. It is expected to cut gross annual pre-tax operating expenses by approximately $175 million by the end of 2027. A new Manufacturing Network Optimization Plan started in September 2026 and is expected to cost approximately $60 million by the end of 2028.
  • Commitments and debt: The company has committed up to $300 million to a healthcare investment fund. Potential contingent consideration payments on acquisitions range from $0 to $1 billion through 2031. Current debt is $1,287.7 million, including $567.7 million of senior notes due December 13, 2026 and $600.0 million due February 19, 2027.

Follow ZBH in Kortex

The Kortex app shows ZBH's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.